These cases are selected based on their likely precedential value, importance to drug and device manufacturers, and inherent (and subjective) merit. This seminar presents these decisions, and what they mean about the direction of the law in this space, in a more in-depth and informative setting.
CLE Information:
This program is presumptively approved for 1.5 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas and West Virginia. Applications for CLE credit will be filed in Delaware, Florida, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.
CLE questions
